Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 24, 2017 10:23am

138 Views

Post# 26025370

RE:MOA apabetalone (rvx-208)

Thanks for the reminder Toniv. A nice blast from the past to remind us of how far Resverlogix has come with their magic molecule RVX-208. Just to add.....Resverlogix didn't announce that RVX-208 was a bromodomain inhibitor until April 2012. So if you back up to before then, the MOA was even less defined, at least from a non-insider perspective, and RVX-208 was simply a magic bullet to raise hepatic apo-AI production in some mysertious way.

It is truly remarkable that no other company has advanced past pre-clinical with a bromdomain-2 selective BET inhibitor to compete with RVX-208.

BDAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale